Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

The Trump administration plans to announce a deal with pharmaceutical companies to sell discounted weight-loss drugs through ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

U.S. pharmaceutical company Eli Lilly (LLY) says that the weight-loss pill it is developing should be a candidate for ...

BY NOW, YOUR news feed, your dinner table conversations, and your doctor’s office have been flooded with chatter about the ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

A new eye drop, Vizz, was recently FDA approved and is helping people regain near vision without glasses. Originally used for glaucoma, the drops are now repurposed for presbyopia (age-related ...

The Food and Drug Administration approved Novo Nordisk’s NOVO.B-0.26%decrease; red down pointing triangle oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults ...

The compounded retatrutide, developed by Eli Lilly but still in the testing phase, has become popular among fitness influencers on social media. The FDA has sent warning letters to six online ...